Type 2 Diabetes Market to witness growth by 2032, estimates DelveInsight

April 17 06:52 2024
Type 2 Diabetes Market to witness growth by 2032, estimates DelveInsight
Type 2 Diabetes Market
Type 2 Diabetes companies are Eli Lilly, Novo Nordisk, Sanofi, AstraZeneca, Merck & Co., Boehringer Ingelheim, GlaxoSmithKline, Takeda, Roche, Pfizer, Johnson & Johnson, Novartis, Theracos, Lexicon Pharmaceuticals, Hua Medicine Shanghai Ltd, Tonghua Dongbao Pharmaceutical Co Ltd, Jiangsu Hengrui Medicine Co Ltd., Sihuan Pharmaceutical Holdings Group, Biocon Ltd, Oramed Pharmaceuticals, and others.

(Albany, USA) DelveInsight’s “Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Type 2 Diabetes, historical and forecasted epidemiology as well as the Type 2 Diabetes market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Type 2 Diabetes market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Type 2 Diabetes market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Type 2 Diabetes treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Type 2 Diabetes market.

 

Request for a Free Sample Report @ Type 2 Diabetes Market Forecast

 

Some facts of the Type 2 Diabetes Market Report are:

  • According to DelveInsight, Type 2 Diabetes market size is expected to grow at a decent CAGR by 2032.
  • Leading Type 2 Diabetes companies working in the market are Eli Lilly, Novo Nordisk, Sanofi, AstraZeneca, Merck & Co., Boehringer Ingelheim, GlaxoSmithKline, Takeda, Roche, Pfizer, Johnson & Johnson, Novartis, Theracos, Lexicon Pharmaceuticals, Hua Medicine Shanghai Ltd, Tonghua Dongbao Pharmaceutical Co Ltd, Jiangsu Hengrui Medicine Co Ltd., Sihuan Pharmaceutical Holdings Group, Biocon Ltd, Oramed Pharmaceuticals, and others.
  • Key Type 2 Diabetes Therapies expected to launch in the market are PIEMONTE, EMPAGLIFLOZIN, Insulin Efsitora Alfa, Liraglutide, and others.
  • On March 2024, Eli Lilly and Company announced results of a Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 Administered Weekly Using a Fixed Dose Escalation Compared to Insulin Glargine in Insulin-Naïve Adults With Type 2 Diabetes.
  • On April 2024, Pharmasaga Co. Ltd announced results of A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Food Effect and Potential Efficacy of PS1 in Subjects.
  • On April 2024, Eli Lilly and Company announced results of A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared with Placebo in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise Alone (TRANSCEND-T2D-1).
  • On April 2024, Novo Nordisk A/S announced results of a Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec When Switching from Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults with Type 2 Diabetes.
  • On April 2024, Amgen announced results of A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)

 

Type 2 Diabetes Overview

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and relative insulin deficiency. Unlike type 1 diabetes, where the body’s immune system attacks insulin-producing cells, type 2 diabetes typically develops gradually and is influenced by lifestyle factors such as obesity, sedentary lifestyle, and poor diet.

In type 2 diabetes, the body’s cells become resistant to the action of insulin, leading to elevated blood sugar levels. Over time, the pancreas may also fail to produce enough insulin to compensate for this resistance. Symptoms include increased thirst, frequent urination, fatigue, blurred vision, and slow wound healing.

Management of type 2 diabetes involves lifestyle modifications such as weight loss, healthy eating, and regular exercise, along with medications to lower blood sugar levels and improve insulin sensitivity. In some cases, insulin therapy may be necessary. Complications of untreated or poorly managed type 2 diabetes include cardiovascular disease, kidney damage, nerve damage, and vision problems. Early diagnosis and effective management are crucial for preventing complications and maintaining overall health.

 

Learn more about Type 2 Diabetes treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/type-2-diabetes-market

 

Type 2 Diabetes Market 

The Type 2 Diabetes market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Type 2 Diabetes market trends by analyzing the impact of current Type 2 Diabetes therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Type 2 Diabetes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Type 2 Diabetes market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Type 2 Diabetes market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Type 2 Diabetes Epidemiology 

The Type 2 Diabetes epidemiology section provides insights into the historical and current Type 2 Diabetes patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Type 2 Diabetes market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Type 2 Diabetes Epidemiology @ Type 2 Diabetes Market Dynamics

 

Type 2 Diabetes Drugs Uptake

This section focuses on the uptake rate of the potential Type 2 Diabetes drugs recently launched in the Type 2 Diabetes market or expected to be launched in 2019-2032. The analysis covers the Type 2 Diabetes market uptake by drugs, patient uptake by therapies, and sales of each drug.

Type 2 Diabetes Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Type 2 Diabetes market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Type 2 Diabetes Pipeline Development Activities

The Type 2 Diabetes report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Type 2 Diabetes key players involved in developing targeted therapeutics.

 

Request for a sample report to understand more about the Type 2 Diabetes pipeline development activities @ https://www.delveinsight.com/sample-request/type-2-diabetes-market

 

Type 2 Diabetes Therapeutics Assessment

Major key companies are working proactively in the Type 2 Diabetes Therapeutics market to develop novel therapies which will drive the Type 2 Diabetes treatment markets in the upcoming years are Eli Lilly, Novo Nordisk, Sanofi, AstraZeneca, Merck & Co., Boehringer Ingelheim, GlaxoSmithKline, Takeda, Roche, Pfizer, Johnson & Johnson, Novartis, Theracos, Lexicon Pharmaceuticals, Hua Medicine Shanghai Ltd, Tonghua Dongbao Pharmaceutical Co Ltd, Jiangsu Hengrui Medicine Co Ltd., Sihuan Pharmaceutical Holdings Group, Biocon Ltd, Oramed Pharmaceuticals, and others.

 

Learn more about the emerging Type 2 Diabetes therapies & key companies @ https://www.delveinsight.com/sample-request/type-2-diabetes-market

 

Type 2 Diabetes Report Key Insights

1. Type 2 Diabetes Patient Population

2. Type 2 Diabetes Market Size and Trends

3. Key Cross Competition in the Type 2 Diabetes Market

4. Type 2 Diabetes Market Dynamics (Key Drivers and Barriers)

5. Type 2 Diabetes Market Opportunities

6. Type 2 Diabetes Therapeutic Approaches

7. Type 2 Diabetes Pipeline Analysis

8. Type 2 Diabetes Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Type 2 Diabetes Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Type 2 Diabetes Competitive Intelligence Analysis

4. Type 2 Diabetes Market Overview at a Glance

5. Type 2 Diabetes Disease Background and Overview

6. Type 2 Diabetes Patient Journey

7. Type 2 Diabetes Epidemiology and Patient Population

8. Type 2 Diabetes Treatment Algorithm, Current Treatment, and Medical Practices

9. Type 2 Diabetes Unmet Needs

10. Key Endpoints of Type 2 Diabetes Treatment

11. Type 2 Diabetes Marketed Products

12. Type 2 Diabetes Emerging Therapies

13. Type 2 Diabetes Seven Major Market Analysis

14. Attribute Analysis

15. Type 2 Diabetes Market Outlook (7 major markets)

16. Type 2 Diabetes Access and Reimbursement Overview

17. KOL Views on the Type 2 Diabetes Market

18. Type 2 Diabetes Market Drivers

19. Type 2 Diabetes Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting